Ziltivekimab reduced inflammatory biomarkers associated with atherosclerosis in people with chronic kidney disease in phase 2 trial
/PRNewswire/ -- Novo Nordisk today presented results from RESCUE, a phase 2 randomised, double-blind, placebo controlled clinical trial assessing the effect of...
New Jersey United States Paulm Ridker Martin Holst Lange Matt Devalaraja Diabetes Technology Therapeutics
Source: prnewswire.com